Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

IGM Biosciences Q4 EPS $(1.01) Beats $(1.03) Estimate, Sales $651.00K Miss $700.00K Estimate

Author: Happy Mohamed | March 07, 2024 05:41pm
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.03) by 1.94 percent. This is a 15.13 percent increase over losses of $(1.19) per share from the same period last year. The company reported quarterly sales of $651.00 thousand which missed the analyst consensus estimate of $700.00 thousand by 7.00 percent. This is a 75.00 percent increase over sales of $372.00 thousand the same period last year.

Posted In: IGMS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist